Mironid Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$46M
- Investors
-
15
Mironid General Information
Description
Developer of a therapeutic device designed to offer treatment for kidney diseases, chronic inflammatory diseases, and cancer. The company's devices develop proprietary drugs by modulating the activity of key cell-signaling proteins, enabling doctors to improve the health and quality of life of patients by creating high-value therapeutics addressing global unmet medical needs.
Contact Information
Website
www.mironid.comCorporate Office
- Arbuthnott Building, Hamnett Wing
- 161 Cathedral Street
- Glasgow G4 0RE
- Scotland, United Kingdom
Corporate Office
- Arbuthnott Building, Hamnett Wing
- 161 Cathedral Street
- Glasgow G4 0RE
- Scotland, United Kingdom
Mironid Timeline
Mironid Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 05-Aug-2026 | $46M | Completed | Generating Revenue | ||
| 8. Later Stage VC (Series A) | 13-Sep-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series A) | 04-Feb-2021 | Completed | Generating Revenue | |||
| 6. Grant | 01-Apr-2018 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 31-Aug-2017 | Completed | Generating Revenue | |||
| 4. Grant | 30-Jan-2017 | Completed | Generating Revenue | |||
| 3. Seed Round | 10-Jun-2016 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2015 | $781K | Completed | Generating Revenue | ||
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
Mironid Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series A2 | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A | 103,948 | $0.000100 | $28.44 | $28.44 | 1x | $28.44 | 4.56% | |
| Series A | 47,248 | $0.000100 | $68.25 | $68.25 | 1x | $68.25 | 2.07% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Mironid Comparisons
Industry
Financing
Details
Mironid Competitors (72)
One of Mironid’s 72 competitors is CV6 Therapeutics, a Venture Capital-Backed company based in Belfast, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CV6 Therapeutics | Venture Capital-Backed | Belfast, United Kingdom | ||||
| KBP Biosciences | Venture Capital-Backed | Singapore, Singapore | ||||
| Mestag Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Macomics | Venture Capital-Backed | Edinburgh, United Kingdom | ||||
| MiNA Therapeutics | Venture Capital-Backed | London, United Kingdom |
Mironid Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mironid Patents
Mironid Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4572757-A1 | Compounds and their use as pde4 activators | Pending | 17-Aug-2022 | ||
| EP-4572761-A1 | Compounds and their use as pde4 activators | Pending | 17-Aug-2022 | ||
| EP-4572762-A1 | Compounds and their use as pde4 activators | Pending | 17-Aug-2022 | ||
| GB-202211999-D0 | Compounds and their use as pde4 activators | Inactive | 17-Aug-2022 | ||
| GB-202212000-D0 | Compounds and their use as pde4 activators | Inactive | 17-Aug-2022 | C07D519/00 |
Mironid Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mironid Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| The Scottish National Investment Bank | Investment Bank | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| European Investment Fund | Fund of Funds | Minority | ||
| Angel (individual) | Minority |
Mironid FAQs
-
When was Mironid founded?
Mironid was founded in 2014.
-
Where is Mironid headquartered?
Mironid is headquartered in Glasgow, United Kingdom.
-
What is the size of Mironid?
Mironid has 16 total employees.
-
What industry is Mironid in?
Mironid’s primary industry is Therapeutic Devices.
-
Is Mironid a private or public company?
Mironid is a Private company.
-
What is Mironid’s current revenue?
The current revenue for Mironid is .
-
How much funding has Mironid raised over time?
Mironid has raised $78.2M.
-
Who are Mironid’s investors?
The Scottish National Investment Bank, , , European Investment Fund, and are 5 of 15 investors who have invested in Mironid.
-
Who are Mironid’s competitors?
CV6 Therapeutics, KBP Biosciences, Mestag Therapeutics, Macomics, and MiNA Therapeutics are some of the 72 competitors of Mironid.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
